Skip to main content Accessibility help
×
Home
Hostname: page-component-559fc8cf4f-z4vvc Total loading time: 0.268 Render date: 2021-03-03T09:51:19.594Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Article contents

Switching from Antipsychotic to Quetiapine XR Treatment in Patients with Schizophrenia and High from Low Depression Symptoms

Published online by Cambridge University Press:  16 April 2020

S. Ganesan
Affiliation:
University of British Columbia, Vancouver, Canada
I. Eggens
Affiliation:
AstraZeneca, Södertälje, Sweden
K. Huizar
Affiliation:
AstraZeneca, Södertälje, Sweden
D. Meulien
Affiliation:
AstraZeneca, Södertälje, Sweden

Abstract

Purpose:

Assess the efficacy of once-daily extended release quetiapine fumarate (quetiapine XR) in patients with schizophrenia and depressive symptoms.

Methods:

12-week, multi-centre, open-label study in adult patients with schizophrenia (D1444C00147). Patients were cross titrated to quetiapine XR over three days (Day 1: 300 mg; Day 2: 600 mg; Days 3-84: 400-800 mg/day [flexible dosing]). Two patient subsets: high depression symptoms (PANSS depression cluster score ≥ 12) and low depression symptoms (PANSS depression cluster score < 12) at baseline. Change from baseline of PANSS total score and PANSS depression cluster score were analysed by subgroup.

Results:

Mean (SD) change at Day 84 (LOCF) in PANSS depression cluster score was -4.8 (3.3) for patients with high depression (n=109) and -1.1 (2.7) for patients with low depression (n=362). Mean (SD) change from baseline at Day 84 (LOCF) in PANSS total score was -24.3 (18.5) for patients with high depression and -10.5 (18.0) for patients with low depression. at Day 84: in patients switched to quetiapine XR owing to “lack of efficacy”, mean change (SD) from baseline in PANSS depression cluster score was -5.2 (3.2) and -1.3 (2.8) for patients with high and low depression, respectively; in patients switched due to “insufficient tolerability”, mean change (SD) in PANSS depression cluster score was -4.1 (3.5) and -0.6 (2.5) for patients with high and low, respectively.

Conclusions:

Quetiapine XR showed promising results in patients with schizophrenia and depressive symptoms switched from other antipsychotics due to suboptimal efficacy or tolerability. Further randomised, clinical trials are warranted.

Type
P03-141
Copyright
Copyright © European Psychiatric Association 2009
Submit a response

Comments

No Comments have been published for this article.

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 7 *
View data table for this chart

* Views captured on Cambridge Core between 16th April 2020 - 3rd March 2021. This data will be updated every 24 hours.

Access

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Switching from Antipsychotic to Quetiapine XR Treatment in Patients with Schizophrenia and High from Low Depression Symptoms
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Switching from Antipsychotic to Quetiapine XR Treatment in Patients with Schizophrenia and High from Low Depression Symptoms
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Switching from Antipsychotic to Quetiapine XR Treatment in Patients with Schizophrenia and High from Low Depression Symptoms
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *